Full-year results were in line with July’s trading update. Revenues grew by 18% CER, with a stronger-than-expected UK performance (+9% vs +2% in FY 2018), driven in part by the launch of new products, supporting the continued expansion in international markets (+26%) that now account for 55% of group revenues. The expected response to Tristel’s pre-submission request to the FDA, expected in December, should help determine the next steps for US registration. We maintain our FY 2020
16 Oct 2019
Tristel - FY 2019 results: new three-year financial plan
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Tristel - FY 2019 results: new three-year financial plan
Tristel Plc (TSTL:LON) | 442 -22.1 (-1.1%) | Mkt Cap: 210.2m
- Published:
16 Oct 2019 -
Author:
Mark Brewer -
Pages:
16
Full-year results were in line with July’s trading update. Revenues grew by 18% CER, with a stronger-than-expected UK performance (+9% vs +2% in FY 2018), driven in part by the launch of new products, supporting the continued expansion in international markets (+26%) that now account for 55% of group revenues. The expected response to Tristel’s pre-submission request to the FDA, expected in December, should help determine the next steps for US registration. We maintain our FY 2020